| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 5th September 2019 | John Rodney Varner | 1,800 | Open or private purchase | $0.89 | $1,594.62 |
Genprex
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.
Genprex, Inc. is a clinical stage gene therapy company. It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors.
Ticker: GNPX
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1595248
Employees: 8
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
News
Wall Street Breakfast: The Week Ahead
31st January 2021
Stocks To Watch: Earnings Blaze In And More GameStop Mania
30th January 2021
The 17 Stocks That Outperformed Tesla In 2020
21st January 2021